Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Signal Transduction and Targeted Therapy is Scopus-indexed (Q1, CiteScore 81.6), WoS SCIE, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by Springer Nature.
Checked against the index lists dated .
ISSN 2059-3635Verify ISSN ↗2095-9907Verify ISSN ↗
Publisher: Springer Nature
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Genetics | 1 / 357 | 99th | Q1 |
| Cancer Research | 2 / 233 | 99th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2016–present, best quartile Q1, CiteScore 81.6.
Signal Transduction and Targeted Therapy is Q1 in Genetics (rank 1 of 357) and Q1 in Cancer Research (rank 2 of 233), by CiteScore 2025.
Signal Transduction and Targeted Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 81.6, which places it in quartile Q1 at the 99th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 17.740, quartile Q1, with an H-index of 224.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$3,790 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Signal Transduction and Targeted Therapy is published by Springer Nature. Its print ISSN is 2059-3635 and its online ISSN is 2095-9907.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Signal Transduction and Targeted Therapy has an h-index of 286 and a 2-year mean of 50.09 citations per paper (OpenAlex). Its Scopus CiteScore is 81.6, quartile Q1. On 2-year citations it ranks #1 of 353 Scopus journals in Genetics.
Signal Transduction and Targeted Therapy published 428 papers in 2025; its busiest recent year was 2023 with 469. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (41.4%), United States (12%) and South Korea (11.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (1.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.